Results 61 to 70 of about 516,620 (290)

Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

iScience
Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi   +12 more
doaj   +1 more source

Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing

Advanced Science, EarlyView.
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu, Xiyan Wang, Xiaozhen Liu, Chaoqi He, Da Qian, Xuli Meng, Liquan Zhu   +6 more
wiley   +1 more source

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Frontiers in Immunology
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Zhijuan Ai, Zhijuan Ai, Bing Wang, Yunlong Song, Panpan Cheng, Xinlin Liu, Xinlin Liu, Peng Sun   +7 more
doaj   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Biochemistry and Biophysics Reports, 2020
Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection.
Hsiang-Ching Wang, Hui-Chen Hung, Peng-Nien Huang, Yu-An Kung, Sung-Nien Tseng, Yun-Ming Wang, Shin-Ru Shih, John Tsu-An Hsu   +7 more
doaj   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

Advanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He, Xiao Lu, Chang qing Yang, Ran Zhang, Bo Wan, Xin Ni, Dong Mei   +6 more
wiley   +1 more source

Advances of bispecific antibodies using/application in dermatology: a review

Frontiers in Allergy
Bispecific antibodies represent an important innovation in the field of biomedicine in recent years. Compared to monoclonal antibodies, their specific structure enables a single antibody molecule to bind to two different antigens simultaneously.
Ting Zhang, Yang Liu, Pei Xiong Liew, Yu Zhang, Zuotao Zhao   +4 more
doaj   +1 more source

Chemical generation of bispecific antibodies

, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability ...
Lingna Li, Richard A. Lerner, Nancy J. Levin, Abhijit Bhat, Gary Woodnutt, Joselyn Del Rosario, Robert E. Murphy, Michelle Parish, Curt W. Bradshaw, Venkata R. Doppalapudi, Dingguo Liu, Jie Huang, Bryan D. Oates, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Bin Liu, Michael J. Shields, Crystal Hagen, Ping Jin, Rodney W. Lappe, Zemeda Ainekulu   +21 more
core   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

Advanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang, Yanlei Zhang, Shuixiu Peng, Chenchen Hou, Huaqi Guo, Tianyu Zhou, Alex H. Chang, Lifeng Yan, Weining Xiong   +8 more
wiley   +1 more source

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function

, 2017
Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies.
Eric Escobar-Cabrera, Surjit Dixit, Joseph Schrag, Yves Durocher, Dixit, Surjit, Schrag, Joseph, Jason Baardsnes, Paula Lario, Escobar-Cabrera, Eric, Durocher, Yves, Lario, Paula, Baardsnes, Jason   +11 more
core   +1 more source